Under the terms of the agreement, the shareholders of Simulations Plus will receive $18.50 per share, a 26 percent premium over the company’s 60-day volume-weighted average price as of June 15, 2026.
The acquisition will be financed through a mix of committed equity and debt from Altaris-affiliated funds.
Altaris plans to merge Simulations Plus with Chemical Computing Group, another company in its portfolio, which specializes in molecular design software for the pharmaceutical, chemical, and materials industries.
Shawn O’Connor, Chief Executive Officer of Simulations Plus, stated, “The life sciences industry is at an inflection point, as software and services are rapidly evolving toward integrated, AI-driven platforms, cloud-based infrastructure, and more predictable, subscription-based business models.”
 will be acquired by Altaris, LLC in an all-cash transaction, offering shareholders $18.50 per share.){kind=link}